Asset Details
Do you wish to reserve the book?
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Do you wish to request the book?
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
2016
Overview
Patients with grade 2 glioma were randomly assigned to radiation therapy alone or radiation therapy plus six cycles of chemotherapy. The median overall survival with radiation therapy plus chemotherapy was 13.3 years, as compared with 7.8 years with radiation therapy alone.
Grade 2 gliomas are relatively uncommon, constituting 5 to 10% of all primary brain tumors in adults. Progressive neurologic symptoms eventually develop in nearly all patients, and nearly all patients die prematurely. At the time of the initiation of our trial, studies had shown that chemotherapy caused tumor regressions in patients with recurrent low-grade gliomas, with regimens that included procarbazine, lomustine (also called CCNU), and vincristine,
1
carmustine (also called BCNU) plus interferon,
2
and mechlorethamine, vincristine, and procarbazine.
3
Similarly, the combination of procarbazine, CCNU, and vincristine, when administered as initial therapy, has been shown to result in tumor regressions.
4
–
6
The . . .
Publisher
Massachusetts Medical Society
Subject
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biopsy
/ Brain Neoplasms - drug therapy
/ Brain Neoplasms - radiotherapy
/ Female
/ Glioma
/ Humans
/ Lomustine - administration & dosage
/ Male
/ Oligodendroglioma - drug therapy
/ Oligodendroglioma - mortality
/ Oligodendroglioma - radiotherapy
/ Patients
/ Procarbazine - administration & dosage
/ Survival
/ Tumors
